IL228893B - PSD-95 dimer tracers with high affinity as effective neuroprotectants against nizkymochinaiskeim and for the treatment of pain - Google Patents

PSD-95 dimer tracers with high affinity as effective neuroprotectants against nizkymochinaiskeim and for the treatment of pain

Info

Publication number
IL228893B
IL228893B IL228893A IL22889313A IL228893B IL 228893 B IL228893 B IL 228893B IL 228893 A IL228893 A IL 228893A IL 22889313 A IL22889313 A IL 22889313A IL 228893 B IL228893 B IL 228893B
Authority
IL
Israel
Prior art keywords
psd
pain
affinity
efficient
treatment
Prior art date
Application number
IL228893A
Other languages
English (en)
Hebrew (he)
Other versions
IL228893A0 (en
Inventor
Bach Anders
Stromgaard Kristian
Original Assignee
The Univ Of Copenhagen
Bach Anders
Stromgaard Kristian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Copenhagen, Bach Anders, Stromgaard Kristian filed Critical The Univ Of Copenhagen
Publication of IL228893A0 publication Critical patent/IL228893A0/en
Publication of IL228893B publication Critical patent/IL228893B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL228893A 2011-05-13 2013-10-15 PSD-95 dimer tracers with high affinity as effective neuroprotectants against nizkymochinaiskeim and for the treatment of pain IL228893B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161485898P 2011-05-13 2011-05-13
EP11165994 2011-05-13
PCT/EP2012/058762 WO2012156308A1 (en) 2011-05-13 2012-05-11 High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain

Publications (2)

Publication Number Publication Date
IL228893A0 IL228893A0 (en) 2013-12-31
IL228893B true IL228893B (en) 2018-01-31

Family

ID=44367299

Family Applications (1)

Application Number Title Priority Date Filing Date
IL228893A IL228893B (en) 2011-05-13 2013-10-15 PSD-95 dimer tracers with high affinity as effective neuroprotectants against nizkymochinaiskeim and for the treatment of pain

Country Status (13)

Country Link
EP (1) EP2707014B1 (https=)
JP (1) JP6084207B2 (https=)
KR (1) KR102046830B1 (https=)
CN (1) CN103533949B (https=)
AU (1) AU2012257774C1 (https=)
BR (1) BR112013029206B1 (https=)
CA (1) CA2833515C (https=)
DK (1) DK2707014T3 (https=)
ES (1) ES2544573T3 (https=)
IL (1) IL228893B (https=)
PL (1) PL2707014T3 (https=)
SG (1) SG194717A1 (https=)
WO (1) WO2012156308A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014356912B2 (en) 2013-12-01 2019-08-01 University Of Copenhagen Fatty acid derivatives of dimeric inhibitors of PSD-95
CN103804500B (zh) * 2014-01-22 2015-12-30 广州军区广州总医院 用于治疗慢性疼痛的多肽
CN106661126B (zh) * 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
JP7073486B2 (ja) 2017-09-30 2022-05-23 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
CA3089161A1 (en) * 2018-02-02 2019-08-08 Kobenhavns Universitet Compounds for the treatment of acute brain injury
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
CN110787284A (zh) * 2019-11-23 2020-02-14 胡书群 一种治疗缺血性脑损伤的混合小肽tat-shc及其应用
WO2021119756A1 (en) * 2019-12-20 2021-06-24 PYC Therapeutics Limited Novel cellular delivery methods
CN111285923B (zh) * 2020-03-05 2023-02-03 成都奥达生物科技有限公司 一种psd-95抑制剂
US20230346948A1 (en) * 2020-03-06 2023-11-02 University Of Copenhagen Lipid conjugated peptide inhibitors of PICK1
CA3203688A1 (en) * 2021-01-08 2022-07-14 Jonathan David Garman Plasmin-resistant peptides for improved therapeutic index
TW202306965A (zh) 2021-05-12 2023-02-16 哥本哈根大學 Ｐｓｄ－９５抑制劑及其用途
CN114533874B (zh) * 2022-01-27 2023-12-29 北京和舆医药科技有限公司 Psd-95 gk结构域作为神经保护靶点的用途
EP4706670A1 (en) * 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
CN119569824A (zh) * 2023-09-07 2025-03-07 湖南中晟全肽生物科技股份有限公司 作为神经保护剂的药用化合物及其应用
CN118027156B (zh) * 2023-09-07 2024-11-05 湖南中晟全肽生物科技股份有限公司 一种psd-95抑制剂及其用途
CN117164725B (zh) * 2023-09-07 2024-05-10 湖南中晟全肽生物科技股份有限公司 一种突触后密度蛋白-95抑制剂多肽
WO2025215348A1 (en) * 2024-04-08 2025-10-16 The Boots Company Plc Skin wound treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
EP2089052A4 (en) 2006-05-24 2011-02-16 Peg Biosciences POLYETHYLENE GLYCOL-BASED LINK COMPOUNDS AND BIOLOGICALLY ACTIVE CONJUGATES BASED ON SAID COMPOUNDS
WO2008008348A2 (en) * 2006-07-11 2008-01-17 Arbor Vita Corporation Method and compositions for treating stroke with fever
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2010004003A2 (en) * 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction

Also Published As

Publication number Publication date
BR112013029206A2 (pt) 2017-02-14
AU2012257774C1 (en) 2016-11-03
CA2833515A1 (en) 2012-11-22
SG194717A1 (en) 2013-12-30
EP2707014A1 (en) 2014-03-19
CA2833515C (en) 2017-11-28
EP2707014B1 (en) 2015-06-17
KR102046830B1 (ko) 2019-11-20
AU2012257774B2 (en) 2016-07-28
BR112013029206B1 (pt) 2021-05-04
CN103533949A (zh) 2014-01-22
KR20140038435A (ko) 2014-03-28
IL228893A0 (en) 2013-12-31
JP2014514365A (ja) 2014-06-19
AU2012257774A1 (en) 2013-11-07
CN103533949B (zh) 2015-11-25
PL2707014T3 (pl) 2015-12-31
WO2012156308A1 (en) 2012-11-22
ES2544573T3 (es) 2015-09-01
DK2707014T3 (en) 2015-09-14
JP6084207B2 (ja) 2017-02-22

Similar Documents

Publication Publication Date Title
IL228893B (en) PSD-95 dimer tracers with high affinity as effective neuroprotectants against nizkymochinaiskeim and for the treatment of pain
IL251845B (en) Treatment methods using selective bcl-2 inhibitors
PL3444261T3 (pl) Pochodne 2,2-difluoropropionamidowe bardoksolonu metylu, ich kompozycje farmaceutyczne i formy polimorficzne do zastosowania w leczeniu określonych stanów
ZA201401117B (en) Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof
EP2844153A4 (en) METHOD AND DEVICE FOR MINIMALLY INVASIVE SKIN AND SOFT TISSUE INTERFACES
IL253911A0 (en) Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use
ZA201303605B (en) Compounds and methods for treating pain
EP2887805A4 (en) COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
GB201120381D0 (en) Skin treatment apparatus
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
IL230705A0 (en) Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
EP2866830A4 (en) ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 AND ANTI-CXCR5 AGENTS FOR THE INHIBITION OF INFLAMMATION
ITTO20110630A1 (it) Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa
IL229381B (en) Brilacitidine and its results for use in the treatment of mucositis
IL225755A0 (en) Amido-6 derivatives of epoxymorphinans-a5, 4 for the treatment of pain
IL222692A0 (en) Piperazinotriazines as pi3k inhibitors for use in the treatment of antiproliferative disorders
EP2694168A4 (en) HEALTH CARE DEVICE AND METHOD FOR TREATMENT OF PAIN
PL2678307T3 (pl) Zastosowanie pochodnych poliaminoizoprenylu w leczeniu antybiotykami lub środkami antyseptycznymi
EP2651429A4 (en) NEUROPEPTIDE ANALOGUES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
GB201110659D0 (en) composition for skin treatment
GB201110653D0 (en) Composition for skin treatment
GB201016836D0 (en) Composition for skin treatment
GB201016834D0 (en) Composition for skin treatment
PT3539540T (pt) Inibidor de sglt2 1-cloro-4-(beta-d-glucopiranos-1-il)-2-[4-((s)-tetra-hidrofurano-3-iloxi)-benzil]-benzeno em combinação com insulina para utilização num método para redução do risco de hipoglicemia

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed